Lawsuit Filings Warned for Novo, Altimmune, SelectQuote, and Spectrum by Bragar Eagel & Squire, P.C., Urges Affected Investors to Reach Out
In a series of recent developments, three major companies - SelectQuote, Novo Nordisk, and Altimmune - find themselves at the centre of class action lawsuits.
SelectQuote, Inc., a leading online insurance marketplace, is facing a class action lawsuit due to allegations of steering Medicare beneficiaries towards insurers' plans that paid the company the most money, regardless of the plans' quality or suitability. The lawsuit was commenced, but no specific details about the class period, lead plaintiff deadline, or any other relevant information were provided. On May 1, 2025, SelectQuote's stock price fell $0.61, or 19.2%, to close at $2.56 per share on unusually heavy trading volume.
The U.S. Department of Justice (DOJ) has filed a False Claims Act complaint against SelectQuote, alleging that the company engaged in a conspiracy with major insurers to illegally discriminate against beneficiaries deemed to be less profitable. The DOJ further claims that SelectQuote received "tens of millions of dollars" in "illegal kickbacks" from health insurance companies from 2016 to 2021.
Novo Nordisk A/S, a global healthcare company, is another company embroiled in a class action lawsuit. On July 29, 2025, the company announced it was lowering its sales and profit outlook ahead of reporting its results for the second quarter of fiscal year 2025. Following the news, the price of Novo's common stock declined dramatically. From a closing market price of $69.00 per share on July 28, 2025, Novo's stock price fell to $53.94 per share on July 29, 2025, a decline of about 21.83% in the span of just a single day. The class action lawsuit was commenced on behalf of stockholders, with a lead plaintiff deadline of September 30, 2025. The class period is May 7, 2025, to July 28, 2025.
Altimmune, Inc., a biopharmaceutical company, also faces a class action lawsuit due to a dramatic decline in its stock price following the announcement of disappointing topline results from the IMPACT Phase 2b MASH trial of Pemvidutide in the Treatment of MASH. From a closing market price of $7.71 per share on June 25, 2025, Altimmune's stock price fell to $3.61 per share on June 26, 2025, a decline of 53.2% in the span of just a single day. The case was commenced on behalf of stockholders, with a lead plaintiff deadline of October 6, 2025. The class period is August 10, 2023, to June 25, 2025. It's worth noting that there is no public information indicating that Altimmune had a contract with another company or organization involving illegal payments to influence the preference of certain insurance companies before the U.S. Justice Department indictment on May 1, 2025.
Bragar Eagel & Squire, P.C., a nationally recognized law firm representing investors in commercial, securities, derivative, and other complex litigation, is representing investors in these class action lawsuits.
As these cases unfold, investors and stakeholders will be closely watching the developments to understand the implications for each company and the industry as a whole.
